← Eichor
Study identifier: NCT01492972 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Condition: Prostate Cancer  ·  Sponsor: Proton Collaborative Group

PhasePhase 3
Planned participants192
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (4)

Mayo ClinicScottsdale, Arizona, United StatesRecruiting
Northwestern Medicine Chicago Proton CenterWarrenville, Illinois, United StatesRecruiting
Oklahoma Proton CenterOklahoma City, Oklahoma, United StatesRecruiting
Hampton University Proton Therapy InstituteHampton, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT01492972